Knockdown of Mgat5 inhibits breast cancer cell growth with activation of CD4+ T cells and macrophages

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3158-3165

  Li, Dongqing ^a   Li, Yanmei ^b   Wu, Xianglei ^a   Li, Qiao ^c   Yu, Jing ^a   Gen, Jie ^a   Zhang, Xiao Lian ^a  

^a WUHAN UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CYTOKINE; GLYCAN; N ACETYLGLUCOSAMINYL TRANSFERASE V; N ACETYLGLUCOSAMINYLTRANSFERASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ALPHA 1,6 MANNOSYLGLYCOPROTEIN BETA 1,6 N ACETYLGLUCOSAMINYLTRANSFERASE; ALPHA-1,6-MANNOSYLGLYCOPROTEIN BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; GROWTH INHIBITOR; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC TRANSFECTION; GLYCOPROTEIN SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; METABOLISM; METHODOLOGY; PATHOLOGY; PERITONEUM MACROPHAGE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; GROWTH INHIBITORS; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES;

EID: 49149107798     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3158     Document Type: Article

References (28)

1. Rudd, P. M., T. Elliott, P. Creswell, I. A. Wilson, and R. A. Dwek. 2001. Glycosylation and the immune system. Science 291: 2370-2376.
2. Helenius, A., and M. Aebi. 2001. Intracellular function of N-linked glycans. Science 291: 2364-2367.
3. Daniels, M. A., K. A. Hogquist, and S. C. Jameson. 2002. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat. Immunol. 3: 903-909.
4. Zhang, X. L. 2006. Roles of glycans and glycopeptides in immune system and immune-related diseases. Curr. Med. Chem. 13: 1141-1147.
5. Fernandes, B., U. Sagman, M. Auger, M. Demetrio, and J. W. Dennis. 1991. β1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 51: 718-723.
6. Seelentag, W. K., W. P. Li, S. F. Schmitz, U. Metzger, P. Aeberhard, P. U. Heitz, and J. Roth. 1998. Prognostic value of β 1, 6-branched oligosaccharides in human colorectal carcinoma. Cancer Res. 8: 5559-5564.
7. Handerson, T., R. Camp, M. Harigopal, D. Rimm, and J. Pawelek. 2005. β 1, 6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin. Cancer Res. 11: 2969-2973.
8. Nakahara, S., T. Saito, N. Kondo, K. Moriwaki, K. Noda, S. Ihara, M. Takahashi, Y. Ide, J. Gu, H. Inohara, et al. 2006. A secreted type of β1, 6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by γ-secretase. FASEB J. 20: 2451-2459.
9. Cummings, R. D., and S. Kornfeld. 1982. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J. Biol. Chem. 257: 11230 -11234.
10. Taeda, Y., M. Nose, S. Hiraizumi, and N. Ohuchi. 1996. Expression of L-PHA-binding proteins in breast cancer: reconstitution and molecular characterization of β 1-6 branched oligosaccharides in three-dimensional cell culture. Breast Cancer Res. Treat. 38: 313-324.
11. Fernandes, B., U. Sagman, M. Auger, M. Demetrio, and J. W. Dennis. 1991. β 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 51: 718-723.
12. Granovsky, M., J. Fata, J. Pawling, W. J. Muller, R. Khokha, and J. W. Dennis. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. 6: 306-312.
13. Morgan, R., G. Gao, J. Pawling, J. W. Dennis, M. Demetriou, and B. Li. 2004. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J. Immunol. 173: 7200-7208.
14. Demetriou, M., M. Granovsky, S. Quaggin, and J. W. Dennis. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409: 733-739.
15. Powell, L. D., E. Bause, G. Legler, R. J. Molyneux, and G. W. Hart. 1985. Influence of asparagine-linked oligosaccharides on tumor cell recognition in the mixed lymphocyte reaction. J. Immunol. 135: 714-724.
16. Bowlin, T. L., H. J. McKown, M. S. Kang, and P. S. Sunkara. 1989. Potentiation of human lymphokine-activated killer cell activity by swainsonine, an inhibitor of glycoprotein processing. Cancer Res. 49: 4109-4113.
17. Wang, L., Y. Liang, Z. Li, X. Cai, W. Zhang, G. Wu, J. Jin, Z. Fang, Y. Yang, and X. Zha. 2007. Increase in β1-6 GlcNAc branching caused by N-acetylglucosaminyltransferase V directs integrin β1 stability in human hepatocellular carcinoma cell line SMMC-7721. J. Cell. Biochem. 100: 230-241.
18. Partridge, E. A., C. Le Roy, G. M. Di Guglielmo, J. Pawling, P. Cheung, M. Granovsky, I. R. Nabi, J. L. Wrana, and J. W. Dennis. 2004. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306: 120-124.
19. Guo, P., Q. Y. Wang, H. B. Guo, Z. H. Shen, and H. L. Chen. 2004. N-acetylglucosaminyltransferase V modifies the signaling pathway of epidermal growth factor receptor. Cell Mol. Life Sci. 61: 1795-1804.
20. He, Y. F., X. H. Wang, G. M. Zhang, H. T. Chen, H. Zhang, and Z. H. Feng. 2005. Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol. Immunother. 54: 891-897.
21. He, Y. W., H. Li, J. Zhang, C. L. Hsu, E. Lin, N. Zhang, J. Guo, K. A. Forbush, and M. J. Bevan. 2004. The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat. Immunol. 5: 88-97.
22. Kung, C., J. T. Pingel, M. Heikinheimo, T. Klemola, K. Varkila, L. I. Yoo, K. Vuopala, M. Poyhonen, M. Uharia, M. Rogers, et al. 2000. Mutations in the tyrosine phosphotase CD45 genes in child with sever combine immunodeficiency disease. Nat. Med. 6: 343-345.
23. Wu, T. H., C. N. Pabin, Z. Qin, T. Blankenstein, M. Philip, and J. Dignam. 2004. Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18. J. Immunol. 172: 3243-3251.
24. Glickstein, L. J., and J. L. Coburn. 2006. Association of macrophage inflammatory response and cell death after in vitro Borrelia burgdorferi infection with arthritis resistance. Am. J. Trop. Med. Hyg. 75: 964-967.
25. Alverez, K., C. Haswell, M. St Clair, G. S. Perng, M. Shorebah, M. Pierce, and N. Fregien. 2002. Sequences of the mouse N-acetyglucosaminyltransferase V (Mgat5) mRNA and an mRNA expressed by an Mgat5-defieient cell line. Glycobiology 12: 389-394.
26. Mincey, B. A., F. M. Palmieri, and P. A. Perez. 2002. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist 7: 246-250.
27. Punglia, R. S., M. Morrow, E. P. Winer, and J. R. Harris. 2007. Local therapy and survival in breast cancer. N. Engl. J. Med. 356: 2399-2405.
28. Jellinek, D., L. S. Green, C. Bell, C. K. Lynott, N. Gill, C. Vargeese, G. Kirschenheuter, D. P. McGee, P. Abesinghe, W. A. Pieken, et al. 1995. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34: 11363-11372.